MG-262 (Z-Leu-Leu-Leu-B(OH)2): Reversible Proteasome Inhibitor for Precision Apoptosis and Cell Cycle Research

Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a reversible, cell-permeable proteasome inhibitor with potent chymotryptic activity inhibition (IC50 = 122 nM) under physiological conditions (ps-341.com). It selectively binds the proteasome’s active site, inducing accumulation of ubiquitinated proteins and triggering apoptosis via caspase-3 activation and loss of mitochondrial membrane potential (Nature Metabolism). MG-262 shows dose-dependent inhibition of fibroblast proliferation, collagen expression, and osteoclast differentiation in cell-based assays (mg132.com). The compound is soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL), but not in water, and requires storage at -20°C for stability (APExBIO). It is widely used in cancer, inflammatory, and neurodegenerative disease models to interrogate the ubiquitin-proteasome system and related signaling pathways.

Biological Rationale

The ubiquitin-proteasome system (UPS) is essential for regulated protein degradation in eukaryotic cells. The 26S proteasome degrades polyubiquitinated proteins, controlling cellular processes such as cell cycle progression, apoptosis, and signal transduction (Nature Metabolism). Dysregulation of the UPS contributes to pathologies including cancer, muscle wasting, and neurodegeneration. Proteasome inhibitors like MG-262 allow researchers to dissect UPS functions and study effects on cell fate decisions. MG-262 specifically targets the chymotryptic activity of the proteasome, a crucial step in protein turnover (mg132.com). This selectivity provides a controllable system for inducing proteotoxic stress and monitoring downstream events such as caspase activation, poly(ADP-ribose) polymerase (PARP) cleavage, and modulation of stress-responsive kinases.

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a boronic peptide acid that reversibly and selectively inhibits the chymotryptic activity of the 26S proteasome. The boronic acid moiety forms a covalent but reversible bond with the proteasome’s catalytic threonine residue at the β5 subunit active site (ps-341.com). Inhibition leads to an accumulation of polyubiquitinated substrates, disrupting protein homeostasis. This proteostatic stress triggers cell cycle arrest—typically at the G2/M phase—followed by apoptosis. Apoptosis is mediated through loss of mitochondrial membrane potential, activation of caspase-3, and cleavage of PARP. MG-262 also modulates intracellular signaling, including upregulation of MAP kinase phosphatase-1 and enhanced c-Jun phosphorylation. The compound is cell-permeable, allowing robust inhibition in both cell-based and in vivo settings (APExBIO).

Evidence & Benchmarks

• MG-262 inhibits chymotryptic proteasome activity with an IC50 of 122 nM in biochemical assays (ps-341.com).
• Selective and reversible inhibition of the proteasome leads to rapid accumulation of ubiquitinated proteins in cultured cells (mg132.com).
• MG-262 induces apoptosis via caspase-3 activation and mitochondrial depolarization, confirmed by direct imaging and Western blot analysis (Nature Metabolism).
• In vitro, MG-262 inhibits proliferation and collagen expression in nasal mucosa and polyp fibroblasts in a dose-dependent manner (APExBIO).
• MG-262 reduces osteoclast differentiation in cell-based assays with quantifiable dose-response curves (map-kinase-fragment.com).
• Intravenous administration of MG-262 in animal models inhibits proteasome activity in heart, lung, skeletal muscle, and liver tissues (Nature Metabolism).

Compared to 'MG-262: Reversible Proteasome Inhibitor for Advanced Cell...', this article provides expanded protocols and direct in vivo benchmarks. See also 'MG-262 (Z-Leu-Leu-Leu-B(OH)2): Selective, Reversible Prot...' for biochemical selectivity data; this review extends those findings with apoptosis markers and animal studies.

Applications, Limits & Misconceptions

MG-262 is widely used to interrogate the role of the proteasome in cancer, inflammatory, and neurodegenerative disease models. It enables high-precision proteasome inhibition assays, cell cycle arrest studies, apoptosis research, and studies of the ubiquitin-proteasome system’s crosstalk with autophagy (oprozomib-onx-0912-pr-047.com). As a tool compound, MG-262 delivers dose-dependent, reversible effects and is compatible with both in vitro and in vivo workflows. However, its boronic acid chemistry limits long-term solution stability, and it is not suitable for water-based protocols due to poor solubility. MG-262 is strictly for research use and not approved for clinical applications.

Common Pitfalls or Misconceptions

• MG-262 is not stable in aqueous buffers: Always dissolve in DMSO or ethanol; avoid water-based solutions (APExBIO).
• Long-term storage in solution is unreliable: Prepare fresh solutions before each use; DMSO stocks can be stored at <-20°C for months, but repeated freeze-thaw cycles reduce potency.
• Not selective for non-proteasomal serine proteases: MG-262's activity is specific to the proteasome’s chymotryptic subunit; it does not inhibit unrelated proteases (ps-341.com).
• For research use only: MG-262 is not approved for diagnostic or therapeutic use in humans or animals.
• Proteasome inhibition does not directly block all protein degradation: Other proteolytic pathways (autophagy, lysosomal) remain active (Nature Metabolism).

Workflow Integration & Parameters

For in vitro experiments, dissolve MG-262 at ≥24.57 mg/mL in DMSO or ≥96.4 mg/mL in ethanol. Recommended working concentrations range from 10 nM to 1 μM, depending on cell type and endpoint. For in vivo studies, intravenous dosing regimens must be optimized for target tissue and species, with proteasome inhibition confirmed by activity assays or immunoblotting for ubiquitinated proteins (Nature Metabolism). Store solid MG-262 at -20°C for optimal stability; avoid long-term storage of solutions. Integrate MG-262 into apoptosis and cell cycle arrest protocols alongside controls and orthogonal readouts. Detailed workflow and troubleshooting guidance are available in the APExBIO product documentation (A8179 kit).

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a gold-standard, reversible proteasome inhibitor enabling precise mechanistic research into the ubiquitin-proteasome system, apoptosis, and cell cycle regulation. Its robust selectivity, cell permeability, and benchmarked efficacy in both in vitro and in vivo models make it an essential tool in cancer, muscle aging, and neurodegenerative disease studies. For validated performance and detailed protocols, APExBIO remains a leading supplier of MG-262 for the global research community.